Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4625837 | 1.00 | SPHK1 (0.45) | SPHK1BRD4L3MBTL1HCRTR2HCAR2 | |
| SCHEMBL3086684 | 1.00 | SPHK1 (0.45) | SPHK1BRD4L3MBTL1HCRTR2HCAR2 | |
| SCHEMBL5369635 | 1.00 | SPHK1 (0.45) | SPHK1BRD4L3MBTL1HCRTR2HCAR2 | |
| SCHEMBL3310633 | 1.00 | SPHK1 (0.45) | SPHK1BRD4L3MBTL1HCRTR2HCAR2 | |
| SCHEMBL209962 | 1.00 | SPHK1 (0.45) | SPHK1BRD4L3MBTL1HCRTR2HCAR2 | |
| SCHEMBL8252763 | 0.89 | SPHK1 (0.44) | SPHK1BRD4HCRTR2CHRM2CHRM1 | |
| SCHEMBL6917878 | 0.86 | SPHK1 (0.42) | SPHK1BRD4HCRTR2HCAR2CHRM2 | |
| SCHEMBL15612852 | 0.86 | SPHK1 (0.42) | SPHK1BRD4HCRTR2HCAR2CHRM2 | |
| SCHEMBL13964507 | 0.86 | SPHK1 (0.42) | SPHK1BRD4HCRTR2HCAR2CHRM2 | |
| SCHEMBL14817858 | 0.85 | SPHK1 (0.47) | SPHK1BRD4HCRTR2CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220267356-A1 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2022-08-25 | — | — | US | disclosed |
| EP-4004004-A1 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | AstraZeneca AB (SE) | 2022-06-01 | — | — | EP | disclosed |
| WO-2021014380-A1 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2021-01-28 | — | — | WO | disclosed |
| EP-1864982-B1 | TRIAMINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2012-10-24 | — | — | EP | disclosed |
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-8088796-B2 | Triamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100093785-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20090281074-A1 | DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM | DAIICHI PHARMACEUTICAL CO., LTD (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090239857-A1 | TRIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-24 | — | — | US | disclosed |
| US-7576135-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| US-7342014-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-7312218-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL MYERS SQUIBB CO. (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1864982-A1 | TRIAMINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-12-12 | — | — | EP | disclosed |
| US-20070099922-A1 | SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | HAN WEI | 2007-05-03 | — | — | US | disclosed |
| US-7169795-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| US-20050096309-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239857-A1 | TRIAMINE DERIVATIVE | F2, F12, F3 | SPHK1 2861/4885BRD4 358/4885L3MBTL1 1124/4885 |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | F2, PLAT, MPL | SPHK1 4315/4885BRD4 460/4885L3MBTL1 1698/4885 |
| US-20220267356-A1 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | ARG1, ARG2, PRMT1 | SPHK1 2193/4885BRD4 1485/4885L3MBTL1 2277/4885 |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | SPHK1 3446/4885BRD4 426/4885L3MBTL1 985/4885 |
| US-20100093785-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | SPHK1 3139/4885BRD4 398/4885L3MBTL1 309/4885 |
| US-20070099922-A1 | SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS | TFPI, F12, F5 | SPHK1 3299/4885BRD4 1730/4885L3MBTL1 4018/4885 |
| US-20090281074-A1 | DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM | C1R, C9, F2 | SPHK1 4398/4885BRD4 888/4885L3MBTL1 1605/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | SPHK1 3186/4885BRD4 481/4885L3MBTL1 297/4885 |
| US-20050096309-A1 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | TFPI, F12, F5 | SPHK1 3299/4885BRD4 1730/4885L3MBTL1 4018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.